KNTPFKintor Pharmaceutical Limited
This year, Kintor Pharmaceutical has to prove it can deliver on its most critical catalysts — starting with the NDA submission for KX-826 in October 2026, which anchors the stock at $0.24 and sets the stage for a bull run to $0.32 or a bear collapse to $0.18. The company’s fate hinges on whether it can navigate the next six months of regulatory, clinical, and financial tests without burning through its dwindling cash reserves. If it clears the NDA hurdle and secures a global partner by early 2027, the stock could rally to $0.55. If it fails to meet any of these milestones, the bear path dominates, with the stock sinking toward $0.15 by mid-2027.
The schedule
- Tue20Oct
Expected New Drug Application (NDA) submission to China's NMPA for KX-826 in androgenetic alopecia, following successful Phase 3 topline data.
- Thu10Dec
Initiation of the pivotal Phase 3 trial for GT-20029, the first topical AR-PROTAC candidate for hair loss.
- Wed20Jan
Target window for announcing an ex-China licensing or co-development partner for KX-826 to fund global commercialization.
- Thu25Mar
Full Year 2026 earnings report, detailing KOSHINÉ cosmetics revenue and operating cash burn.
- Thu20May
Expected window for a necessary liquidity event to sustain operations ahead of regulatory approvals.
- Tue10Aug
Final decision by China's NMPA on the approval of KX-826 for male androgenetic alopecia.
